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LONG-CHAIN N-3 OILS: DOES FARMED AUSTRALIAN FISH REMAIN A
BETTER SOURCE OF THE GOOD OIL THAN WILD-CAUGHT FISH?
P.D. Nichols 1, B. Glencross 2, J.P. Petrie 3, S.P. Singh 3. 1CSIRO Food, Nutrition
& Bioproducts; Oceans & Atmosphere Flagships, TAS, Australia; 2CSIRO
Agriculture Flagship, QLD, Australia; 3CSIRO Agriculture Flagship, ACT,
Australia
E-mail: peter.nichols@csiro.au (P.D. Nichols)
Background/Aims: Seafood contains n-3 long-chain ( 20 carbons)
polyunsaturated fatty acids (LC-PUFA, also termed LCn-3 oils). Humans
biosynthesize only small amounts of LCn-3, so they are considered semi-
essential nutrients in our diet. Concern exists that compared to wild-
caught seafood, farmed ﬁsh contain lower LCn-3 content due to use of non-
marine oil in diets. We determined current LCn-3 content and composition
of farmed Australian ﬁsh and also supplements, as consumers increasingly
seek their LCn-3 from the latter.
Methods: Lipids were extracted by standard methods with fatty acids (FA)
analysed as FA methyl esters by GC and conﬁrmed by GC-MS.
Results: We observed that two major farmed ﬁnﬁsh species, Atlantic
salmon and barramundi, have higher oil and LCn-3 content than the same
or other species from the wild, and remain an excellent source for
obtaining substantial intake of these oils. Notwithstanding, in Australia
(and New Zealand) LCn-3 oil content has decreased in these two farmed
species, largely resulting from the replacement of dietary ﬁsh oil with
poultry oil. For Atlantic salmon, LCn-3 content decreased ~30%e50% be-
tween 2002 and 2013, and the n-3:n-6 ratio also decreased (> 5:1 to < 1:1).
For the supplements compared, all met LCn-3 speciﬁcations.
Conclusions: The development and application of new oilseeds containing
LCn-3 oils, and their incorporation in aquafeeds, will enable the content of
these oils to be maximized in farmed seafood. Such advances can assist
with: ﬁsheries management, aquaculture nutrition, an innovative feed/
food industry and ultimately towards improved consumer health.
Funding source(s): CSIRO.
POTENTIAL FOR LONG CHAIN N-3 PUFA SYNTHESIS IN POULTRY:
CHARACTERISATION OF THE CHICKEN, TURKEY AND DUCK ELONGASE
ENZYMES
M.K. Gregory 1, M.S. Geier 2, M.J. James 1. 1Rheumatology Unit, Royal
Adelaide Hospital, SA, Australia; 2 South Australian Research and
Development Institute, Pig and Poultry Production Institute, Roseworthy,
SA, Australia
E-mail: melissa.gregory@health.sa.gov.au (M.K. Gregory)
Background/Aims: Poultry could be a useful source of non-ﬁsh derived
EPA and DHA if they are capable of synthesizing these n-3 PUFA from di-
etary plant-derived a-linolenic acid. The ability to elongate docosa-
pentaenoic acid (DPA; 22:5n-3) to 24:5n-3 is a crucial and limiting reaction
for synthesis of DHA.We examined the activities of the chicken, turkey and
duck elongase enzymes, Elovl5 and Elovl2.
Methods: Saccharomyces cerevisiae expressing the chicken, turkey or duck
Elovl2orElovl5werecultured in thepresenceofvariousC18-22PUFAsubstrates
to determine the substrate speciﬁcity and dose response of the enzymes.
Results: The turkey and duck Elovl5 activity was limited to C18 and C20
PUFA substrates. The chicken Elovl5 activity was unique compared to
turkey and duck as it also elongated DPA to 24:5n-3 with 20% conversion.
Conversion was undetectable for turkey and duck Elovl5. The duck Elovl2
selectivity was broad with elongation of C18-22 PUFA substrates compared
to the more restricted chicken or turkey Elovl2 selectivity towards C20 and
C22 PUFA substrates only. EPA dose response curves indicate that the duck
Elovl2was the most efﬁcient to catalyse the sequential elongation reaction
EPA to DPA to 24:5n-3.
Conclusions: The combined activity of the chicken Elovl5 and Elovl2 to
convert DPA to 24:5n-3 may enable chickens to synthesize more 24:5n-3
and subsequently more DHA compared with turkey and duck. However,
the duck Elovl2 was particularly active in elongating EPA and DPA to 24:5n-
3 indicating a capability for DHA synthesis that could be exploited.
Funding source(s): N/A.EFFECT OF FISH OIL ON CLINICAL OUTCOMES IN RECENT ONSET
RHEUMATOID ARTHRITIS
M.J. James 1, S.M. Proudman 1, R.G. Metcalf 1, L.D. Spargo 1, T.R.
Sullivan 2, L.G. Cleland 1. 1Rheumatology Unit, Royal Adelaide Hospital, SA,
Australia; 2Discipline of Public Health, University of Adelaide, SA, Australia
E-mail: michael.james@health.sa.gov.au (M.J. James)
Background/Aims: To examine the effect of a ﬁsh oil intervention on
disease control and disease-modifying anti-rheumatic drug (DMARD)
effectiveness in recent onset rheumatoid arthritis (RA) with follow-up
analysis of the relationships between plasma levels of the n-3 fatty acids,
EPA and DHA, and the same outcome measures.
Methods: We conducted a double-blind randomised controlled trial (RCT)
of high dose ﬁsh oil versus control in recent onset RA treated with a rules-
based drug algorithm, responsive to disease activity and toxicity. This
allowed DMARD use (in fact failure of DMARDs to achieve disease control)
to be a primary outcome measure along with remission. As well as the
analysis by treatment group, relationships between plasma EPA and DHA
and the primary outcomes were examined.
Results: Compared to the control group, the ﬁsh oil group had an increased
rate of remission (HR 2.09, 95%CI: 1.02, 4.30, p ¼ 0.04) and decreased rate
of DMARD failure (RR 0.24, 95%CI: 0.10, 0.54, p ¼ 0006). Plasma EPA was
favourably associated with time to remission (HR 1.12, 95%CI: 1.02, 1.23, p
¼ 0.017) and time to DMARD failure (HR 0.85, 95%CI: 0.72, 0.99, p¼ 0.047).
The HRs for DHA and the same outcomes were similar to those for EPA but
not statistically signiﬁcant.
Conclusions: An RCT demonstrated increased ACR remission and decreased
DMARD failure in the ﬁsh oil group. Follow-up analysis was consistent with
the RCT results in demonstrating favourable relationships between plasma
EPA and the sameoutcomemeasures. Anti-inﬂammatory doses ofﬁshoil can
provide adjunctive therapy for standard drug treatment of recent onset RA.
Funding source(s): NHMRC.
BIOAVAILABILITY OF FISH OIL VS KRILL OIL e INFLUENCE OF GENDER
S. Ghasemi Fard 1, G.M. Turchini 2, A.J. Sinclair 1. 1Metabolic Research Unit,
School of Medicine, Deakin University, Geelong, Australia; 2 School of Life
and Environmental Sciences, Deakin University, Warrnambool, Australia
E-mail: sghasemi@deakin.edu.au (S. Ghasemi Fard)
Background/Aims: Krill oil is an alternative source of n-3 fatty acids (FAs).
There are conﬂicting results from the studies comparing the effects of ﬁsh
oil and krill oil.
Objective: The aim of this study was to compare the true bioavailability of
n-3 FAs from ﬁsh oil and krill oil in rats of both genders, using the whole
body fatty acid balance method (WBFABM).
Design: Sprague Dawley rats (36male, 36 female) were randomly assigned
to 6 groups after one week acclimatization, were fed to constant ration for
6 weeks on either a krill oil diet (KO: 10% fat, EPA+DHA¼ 19.8 mg/g of diet)
or a ﬁsh oil diet (FO: 10% fat, EPA+DHA¼ 20.5 mg/g of diet). The faeces and
whole body were analysed for fatty acid content.
Outcomes: Krill oil and ﬁsh oil supplementation led to approximately
similar levels of EPA and DHA in the whole body in both genders. More than
90% of the EPA ingested was b-oxidised in both diets. More than 60% of the
DHA was b-oxidised; which was signiﬁcantly higher in FO than KO. The
amount of DHA deposited was signiﬁcantly more in KO than FO. More than
80% of docosapentaenoic acid was deposited in KO compared with 35% in
FO. In contrast, less than 10% of KOwas b-oxidised comparedwith 60% in FO.
Conclusions: The results suggested that krill oil and ﬁsh oil n-3 FAs have
different metabolic fate.
Funding source(s): Molecular Medicine Strategic Research Centre Deakin
University.
ERYTHROCYTE LONG CHAIN N-3 PUFA LEVEL IS A PREDICTOR OF BODY
WEIGHT STATUS IN OLDER AUSTRALIANS
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